Whilst these results are disappointing and IPO holders have been...

Whilst these results are disappointing and IPO holders have been cut in half, there still is plenty of potential application for Flavocide.

Bio-gene have announced their tech has been effective on mosquitos, red legged earthmites and others. Virbac was only interested in the animal health application. I'm sure other companies will be happy to partner up and take Flavocide further.

Any results will provide plenty of insight for management when they get their hands on the data.

I can't see the benefit in selling at these giveaway prices. A massive setback nonetheless.